Trial reportGraefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie2016
Clinical efficiency of Helicobacter pylori eradication in the treatment of patients with acute central serous chorioretinopathy.
Trial report in Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 3 syntheses or guidelines pooled it.
- Oral therapeutic interventions for central serous chorioretinopathy: A systematic review.Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie · 2026Pooled it
- Interventions for central serous chorioretinopathy: a network meta-analysis.The Cochrane database of systematic reviews · 2025Pooled it
- Comparing treatment outcomes in randomized controlled trials of central serous chorioretinopathy.Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie · 2023Pooled it
- Randomized controlled trials in central serous chorioretinopathy: A review.Eye (London, England) · 2023Review
- Inhibition of Bacterial Peptidoglycan Cytopathy by Retina Pigment Epithelial PGRP2 Amidase.Advances in experimental medicine and biology · 2023Article
- Review
- OCT Evaluation of Retinal Parameters in Pediatric Gastritis Patients with Helicobacter Pylori.Beyoglu eye journal · 2021Article
- Extra-Gastric Manifestations ofJournal of clinical medicine · 2020Review
- Current Pharmacological Treatment Options for Central Serous Chorioretinopathy: A Review.Pharmaceuticals (Basel, Switzerland) · 2020Review
- Oral medications for central serous chorioretinopathy: a literature review.Eye (London, England) · 2020Review
- The evaluation of the effect of Helicobacter pylori infection on choroidal thickness.The Turkish journal of gastroenterology : the official journal of Turkish Society of Gastroenterology · 2018Article
- Review
- Diagnosed a Patient with Central Serous Chorioretinopathy? Now What?: Management of Central Serous Chorioretinopathy.Current ophthalmology reports · 2017Article
- Is Helicobacter pylori the culprit behind central serous chorioretinopathy?Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie · 2016Article
- Helicobacter pylori is the culprit behind central serous chorioretinopathy.Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie · 2016Article
Corrections and comments
- Commented on by
- Commented on by
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundAlthough the majority of cases of acute central serous chorioretinopathy are self-limited, resolving spontaneously after a number of weeks, the recurrence rate is estimated to be 20-50 %, and some cases will be chronic, lasting 6 months or longer. The evidence of Helicobacter pylori infection appears more often in patients with central serous chorioretinopathy. The purpose of this work was to estimate the efficiency of H. pylori infection eradication in treatment of patients with acute central serous chorioretinopathy.
methodsNinety-three patients with acute central serous chorioretinopathy participated in this study. Patients were divided into an experimental group (33 Helicobacter pylori-positive patients who received eradication treatment) and two control groups who did not receive eradication treatment: 29 H. pylori-positive patients and 31 H. pylori-negative patients. Research methods were best-corrected Snellen visual acuity, optical coherence tomography, fluorescein angiography. Research methods were best-corrected Snellen visual acuity, optical coherence tomography, static perimetry, and Amsler grid. The follow-up period was 2 years.
resultsHelicobacter pylori eradication caused a decrease of disease duration at 3 months (p = 0.04) and recurrence frequency of 45.6 % (p = 0.03) as well as improvement of distant prognosis. After 2 years, visual acuity increased from 0.91 ± 0.07 to 0.99 ± 0.02 (p = 0.01), scotoma frequency decreased from 100 % eyes to 27.2 % (p = 0.001), and metamorphopsia frequency decreased from 57.6 % eyes to 39.4 % (p = 0.04).
conclusionsHelicobacter pylori eradication is effective in the treatment of H. pylori-positive patients with acute central serous chorioretinopathy.
Indexed as
Identifiers
26979068What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.